Liu Xiaojie, Liu Junru, Liu Lyuye, Yu Jipeng, Gao Dejing, Zhou Tianyuan, Xing Weibin
Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, No. 354, North Road, Hongqiao District, Tianjin 300120, China.
The Second Department of Dermatology, Yantai Yuhuangding Hospital, Yuhuangding East Road 20, Yantai, Shandong 264099, China.
Photodiagnosis Photodyn Ther. 2025 Oct;55:104730. doi: 10.1016/j.pdpdt.2025.104730. Epub 2025 Jul 24.
Basal cell carcinoma (BCC) is the most common non-pigmented cutaneous malignancy.ALA-PDT has significant advantages in the treatment of BCC, but it is limited by the size and depth of the tumor. Combination therapy can improve the efficacy of PDT in treating BCC and overcome its limitations.
A retrospective study was conducted to analyze the feasibility of ET combined with ALA-PDT in the treatment of high-risk BCC in terms of efficacy, aesthetic outcome, patient satisfaction, quality of life, and adverse reactions.
High-risk BCC treated with ET combined with ALA-PDT showed a cure rate of 98.55 % and a recurrence rate of 1.45 % at 1 year or more (average follow-up of 31 months). The treatment showed excellent aesthetic results (scar score of 1.87) and high patient satisfaction (8.03). The quality of life of the treated patients significantly improved compared to the pre-treatment period (DLQI of 13.03 and 1.94 points), and the difference was statistically significant. The average healing time was 16.81 days after treatment. The main adverse reactions were moderate pain (4.90 points) and local redness and swelling, and no infection was observed.
ET combined with PDT showed remarkable efficacy in the treatment of high-risk BCC. The combination provides rapid healing, less scarring, and good aesthetic outcomes, which can be used as a clinical choice for treating high-risk BCC. However, it still needs to be verified in studies with larger sample sizes and longer follow-up periods.
